Antal patienter, som har fået SonoVue i kliniske undersøgelser, i forbindelse med efterfølgende tilstande, er begrænset, og derfor tilrådes forsigtighed, når præparatet gives til patienter med: akut endocarditis, kunstige hjerteklapper, akut systemisk inflammation og/ eller sepsis, hyperaktiv koagulations tilstand og/ eller nylig thromboemboli og slut stadie af renal eller hepatisk sygdom.
Numbers of patients with the following conditions who were exposed to SonoVue in the clinical trials were limited, and therefore, caution is advisable when administering the product to patients with: acute endocarditis, prosthetic valves, acute systemic inflammation and/ or sepsis, hyperactive coagulation states and/ or recent thromboembolism, and end-stage renal or hepatic disease.